MERSANA THERAPEUTICS INC (MRSN) Stock Overview
USA - NASDAQ:MRSN - US59045L2051 - Common Stock
MRSN Key Statistics, Chart & Performance
The current stock price of MRSN is 9.24 USD. In the past month the price increased by 29.41%. In the past year, price decreased by -81.24%.
MRSN Latest News, Press Relases and Analysis
MRSN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.77 | 407.19B | ||
| AMGN | AMGEN INC | 13.3 | 156.19B | ||
| GILD | GILEAD SCIENCES INC | 15.14 | 145.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.07 | 104.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.37 | 59.85B | ||
| ARGX | ARGENX SE - ADR | 85.97 | 48.77B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.17 | 35.16B | ||
| INSM | INSMED INC | N/A | 34.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
| NTRA | NATERA INC | N/A | 23.23B | ||
| BIIB | BIOGEN INC | 9.15 | 21.49B |
Related stock screener links
About MRSN
Company Profile
Mersana Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The firm's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Company Info
MERSANA THERAPEUTICS INC
840 Memorial Dr
Cambridge MASSACHUSETTS 02139 US
CEO: Anna Protopapas
Employees: 102
Phone: 16174980020
MERSANA THERAPEUTICS INC / MRSN FAQ
What is the stock price of MERSANA THERAPEUTICS INC today?
The current stock price of MRSN is 9.24 USD. The price increased by 1.87% in the last trading session.
What is the ticker symbol for MERSANA THERAPEUTICS INC stock?
The exchange symbol of MERSANA THERAPEUTICS INC is MRSN and it is listed on the Nasdaq exchange.
On which exchange is MRSN stock listed?
MRSN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MERSANA THERAPEUTICS INC stock?
15 analysts have analysed MRSN and the average price target is 74.31 USD. This implies a price increase of 704.27% is expected in the next year compared to the current price of 9.24. Check the MERSANA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MERSANA THERAPEUTICS INC worth?
MERSANA THERAPEUTICS INC (MRSN) has a market capitalization of 46.11M USD. This makes MRSN a Nano Cap stock.
How many employees does MERSANA THERAPEUTICS INC have?
MERSANA THERAPEUTICS INC (MRSN) currently has 102 employees.
What are the support and resistance levels for MERSANA THERAPEUTICS INC (MRSN) stock?
MERSANA THERAPEUTICS INC (MRSN) has a support level at 7.97 and a resistance level at 9.45. Check the full technical report for a detailed analysis of MRSN support and resistance levels.
Is MERSANA THERAPEUTICS INC (MRSN) expected to grow?
The Revenue of MERSANA THERAPEUTICS INC (MRSN) is expected to decline by -18.41% in the next year. Check the estimates tab for more information on the MRSN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MERSANA THERAPEUTICS INC (MRSN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MRSN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MRSN, evaluating the profitability, health, valuation and growth aspects
- MERSANA THERAPEUTICS INC (MRSN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MERSANA THERAPEUTICS INC (MRSN) Sales and EPS estimates to see what analysts future expectations are.
- MERSANA THERAPEUTICS INC (MRSN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MERSANA THERAPEUTICS INC (MRSN) Insider and Institutional Ownership to learn about the owners and their transactions.
- MERSANA THERAPEUTICS INC (MRSN) Stock Chart to make your own analysis
- MERSANA THERAPEUTICS INC (MRSN) Latest news and press-releases to stay up to date.
Does MERSANA THERAPEUTICS INC (MRSN) stock pay dividends?
MRSN does not pay a dividend.
When does MERSANA THERAPEUTICS INC (MRSN) report earnings?
MERSANA THERAPEUTICS INC (MRSN) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of MERSANA THERAPEUTICS INC (MRSN)?
MERSANA THERAPEUTICS INC (MRSN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.62).
What is the Short Interest ratio of MERSANA THERAPEUTICS INC (MRSN) stock?
The outstanding short interest for MERSANA THERAPEUTICS INC (MRSN) is 8.69% of its float. Check the ownership tab for more information on the MRSN short interest.
MRSN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MRSN. When comparing the yearly performance of all stocks, MRSN is a bad performer in the overall market: 94.43% of all stocks are doing better.
MRSN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MRSN. MRSN may be in some trouble as it scores bad on both profitability and health.
MRSN Financial Highlights
Over the last trailing twelve months MRSN reported a non-GAAP Earnings per Share(EPS) of -14.62. The EPS decreased by -161.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.54% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRSN Forecast & Estimates
15 analysts have analysed MRSN and the average price target is 74.31 USD. This implies a price increase of 704.27% is expected in the next year compared to the current price of 9.24.
For the next year, analysts expect an EPS growth of 12.56% and a revenue growth -18.41% for MRSN